A heavily promoted heart drug endorsed by the National Institute for Health and Clinical Excellence (NICE) may be worthless, according to a newly published trial. Ezetimibe (Ezetrol) was recommended by NICE last year for patients with inherited high cholesterol, to be used in conjunction with a statin drug such as simvastatin. But results published in the New England Journal of Medicine and presented yesterday at the American College of Cardiology annual scientific session in Chicago show that it may add nothing to the effectiveness of the statin.
Link to Article
Drugs companies Merck and Schering-Plough ‘suppressed Ezetrol trial results’ - The Times 31st March 2008
Monday, March 31, 2008
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment